BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)
China flag China · Delayed Price · Currency is CNY
35.23
-0.89 (-2.46%)
At close: Sep 11, 2026

SHA:688166 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
96.2754.51189.17202.47239.62243.95
Depreciation & Amortization
166.54157.87111.4178.0650.4741.5
Other Amortization
10.5212.629.1910.5411.0910.83
Loss (Gain) From Sale of Assets
-0.01----0.01-0.01
Asset Writedown & Restructuring Costs
-8.469.498.391.751.570.26
Loss (Gain) From Sale of Investments
-2.32-0.911.9712.41-3-10.02
Provision & Write-off of Bad Debts
47.2919.6911.570.9-2.2310.11
Other Operating Activities
104.2659.9620.4637.19-1.088.27
Change in Accounts Receivable
-142.2936.53-149.93-17.854.96-241.94
Change in Inventory
32.14-5.96-35.55-85.77-94.94-6.25
Change in Accounts Payable
-56.221.7984.4-23.61130.2116.92
Change in Other Net Operating Assets
15.2711.5215.75-2.96-21.314.16
Operating Cash Flow
226.81325.19245.56194.77311.26176.08
Operating Cash Flow Growth
9.07%32.43%26.08%-37.43%76.78%13.28%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-242.16-453.41-257.2-403.76-726.73-909.66
Sale of Property, Plant & Equipment
0.070.040.30.480.380.05
Cash Acquisitions
----0.01-7.5
Investment in Securities
-276.78-205.99-228.61-64.24-153.388.64
Other Investing Activities
33.1936.8145.3731.2618.2418.64
Investing Cash Flow
-485.68-622.54-440.14-439.85-871.58-889.84

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-1,065823.08678.231,646882.2
Total Debt Issued
1,9441,065823.08678.231,646882.2
Long-Term Debt Repaid
--870.26-804.81-569.61-474.12-210.88
Lease Payments
-7.38-15.71-16-9.52--
Total Debt Repaid
-1,182-870.26-804.81-569.61-474.12-210.88
Net Debt Issued (Repaid)
761.73194.7918.27108.621,172671.32
Issuance of Common Stock
51.8---219.81-
Repurchase of Common Stock
-10.04-10.04-10.01---
Common Dividends Paid
-87.22-117.6-135.73-115.01-100.1-54.3
Other Financing Activities
137.24430.51103687386.7
Financing Cash Flow
853.52497.65-24.4761.611,365703.72

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-13.160.662.122.7814.153.72
Net Cash Flow
581.49200.96-216.94-180.69818.52-6.32

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-15.35-128.22-11.64-209-415.47-733.59
Free Cash Flow Growth
------
Free Cash Flow Margin
-1.13%-10.48%-0.91%-17.72%-40.84%-69.71%
Free Cash Flow Per Share
-0.04-0.31-0.03-0.49-1.01-1.80
Levered Free Cash Flow
462.27-256.49-72.62-316.64-515.42-785.87
Unlevered Free Cash Flow
507.63-217.14-39.85-288.87-500.6-779.81
Free Cash Flow After Leases
-22.73-143.93-27.64-218.52-415.47-733.59

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Income Tax Paid
14.3218.8225.4629.42-17.03-7.18
Change in Working Capital
-187.2911.95-116.59-148.5414.83-128.81